Loading clinical trials...
Loading clinical trials...
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation
Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Mendoza, Mendoza Province, Argentina
Novartis Investigative Site
Mendoza, Mendoza Province, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Tucumán Province, Argentina
Novartis Investigative Site
Antwerp, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Genk, Belgium
Start Date
December 1, 2013
Primary Completion Date
September 1, 2014
Completion Date
September 1, 2014
Last Updated
November 11, 2013
QVA149
DRUG
fluticasone/salmeterol
DRUG
Lead Sponsor
Novartis Pharmaceuticals
NCT07477600
NCT05878769
NCT06717659
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions